Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
20%(1 trials)

Phase Distribution

Ph phase_4
2
25%
Ph not_applicable
2
25%
Ph phase_2
2
25%
Ph phase_1
2
25%

Phase Distribution

2

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
2(25.0%)
Phase 4Post-market surveillance
2(25.0%)
N/ANon-phased studies
2(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(5)
Terminated(2)
Other(1)

Detailed Status

Completed5
Withdrawn2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (25.0%)
Phase 22 (25.0%)
Phase 42 (25.0%)
N/A2 (25.0%)

Trials by Status

unknown113%
withdrawn225%
completed563%

Recent Activity

0 active trials
Showing 5 of 8
completednot_applicable

Effect of Methyldopa on MHC Class II Antigen Presentation in Type 1 Diabetes

NCT01883804
unknownphase_4

Early Vascular Adjustments During Hypertensive Pregnancy

NCT02531490
withdrawnphase_2

Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes

NCT03396484
completednot_applicable

Community Level Interventions for Pre-eclampsia

NCT01911494
completedphase_4

Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy

NCT01912677
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT01883804Not Applicable

Effect of Methyldopa on MHC Class II Antigen Presentation in Type 1 Diabetes

Completed
NCT02531490Phase 4

Early Vascular Adjustments During Hypertensive Pregnancy

Unknown
NCT03396484Phase 2

Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes

Withdrawn
NCT01911494Not Applicable

Community Level Interventions for Pre-eclampsia

Completed
NCT01912677Phase 4

Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy

Completed
NCT00194974Phase 1

Treatment Targets for Chronic Hypertension in Pregnancy

Withdrawn
NCT00580619Phase 1

Autonomic Nervous System and Chronic Fatigue Syndrome

Completed
NCT01674127Phase 2

Effect of Methyldopa on Uterine Artery Diameter in Pregnant Women With Mild Preeclampsia

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8